Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
64 studies found for:    Open Studies | "Peritoneal Diseases"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Peritoneal Diseases"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Diagnosis of Spontaneous Bacterial Peritonitis
Condition: Spontaneous Bacterial Peritonitis
Intervention: Other: Diagnostic tests
2 Recruiting A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Condition: Recurrent Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Cancer,
Interventions: Biological: Vaccine--‐primed, CD3/CD28--‐costimulated autologous peripheral blood T--‐cells;   Biological: SB--‐485232 (Human recombinant Interleukin--‐18)
3 Recruiting INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: IDO1 Inhibitor INCB024360;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
4 Recruiting Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure
Condition: Spontaneous Bacterial Peritonitis (SBP).
Interventions: Drug: cefepime + Albumin;   Drug: Imipenem + Albumin
5 Recruiting Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients
Condition: Spontaneous Bacterial Peritonitis
Interventions: Drug: Rifaximin;   Drug: Ciprofloxacin
6 Recruiting Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: folate receptor alpha-loaded dendritic cell vaccine;   Other: laboratory biomarker analysis
7 Unknown  Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients
Condition: Peritonitis
Interventions: Drug: ceftazidime+ciprofloxacin;   Drug: ceftazidime monotherapy;   Drug: cefazolin+gentamicin;   Drug: cefazolin monotherapy
8 Unknown  Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
Conditions: Breast Cancer;   Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer;   Prostate Cancer;   Sarcoma;   Vaginal Cancer;   Vulvar Cancer
Interventions: Genetic: gene expression analysis;   Genetic: gene rearrangement analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Radiation: radiation therapy
9 Recruiting Different Retraining Methods vs Usual Care on the Prevention of Peritonitis in Peritoneal Dialysis
Condition: Peritonitis
Intervention: Behavioral: operation inspection
10 Recruiting "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs);   Biological: Interleukin-2
11 Recruiting IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis
Condition: Suspected Tuberculous Peritonitis
Intervention: Other: Blood and Ascites ELISPOT
12 Unknown  Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
13 Unknown  Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
Conditions: Spontaneous Bacterial Peritonitis;   Cirrhosis
Interventions: Drug: Standard Care;   Drug: Experimental
14 Recruiting A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
15 Recruiting BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer
Condition: Ovarian Cancer, Peritoneal Neoplasms
Intervention:
16 Recruiting A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Oral rucaparib
17 Recruiting Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Recurrent Epithelial Ovarian Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Primary Peritoneal Cancer
Intervention: Drug: Tivozanib
18 Not yet recruiting Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: metformin hydrochloride;   Drug: placebo;   Other: laboratory biomarker analysis
19 Recruiting HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry
Conditions: Peritoneal Neoplasms;   Neoplasm Metastasis;   Adenocarcinoma;   Sarcoma
Intervention:
20 Not yet recruiting Adjuvant HIPEC in High Risk Colon Cancer
Conditions: Colorectal Neoplasms;   Peritoneal Neoplasms
Interventions: Procedure: Adjuvant HIPEC (open/laparoscopic);   Drug: Standard adjuvant systemic chemotherapy;   Procedure: Diagnostic laparoscopy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years